Investing.com - Financial Markets Worldwide

Lonza releases financials for new ’One Lonza’ model ahead of 1H25 results

Published 27/05/2025, 09:36
© Reuters.
LONN
-1.12%

Investing.com -- Lonza Group AG (SWX:LONN) today unveiled its comparative financials for its newly implemented operating model, ’One Lonza’, for the fiscal year 2024 and the first half of 2024, ahead of its first-half results for 2025, which are due on July 23.

The ’One Lonza’ model, which became effective from April 1, 2025, includes three Contract Development and Manufacturing Organization (CDMO) business segments and the soon-to-be-divested Capsules business.

The Integrated Biologics segment includes the Mammalian and Drug Product Services technologies, along with the Licensing business. The Advanced Synthesis segment comprises the Small Molecules and Bioconjugates technologies business. Specialized Modalities includes the Cell & Gene, mRNA, Microbial technologies, and Bioscience products. The Capsules segment remains unchanged.

According to the released financials, Bioconjugates had a margin in line with Small Molecules, indicating no change in the Advanced Synthesis division margin. Moreover, Bioconjugates accounted for approximately 10% of Biologics revenues.

However, the capital expenditures (Capex) for Bioconjugates were reported to be CHF151 million, making up 18% of Biologics Capex allocation. This suggests a clear investment in the future growth of this particular segment.

The Microbial and mRNA segments have a combined implied margin of 20%, which is accretive to the Cell & Gene Therapies (CGT) division margin, but dilutive to the Biologics margin. These two segments were allocated less Capex, 8% of Biologics Capex spend, compared to their contribution of 11% to Biologics Revenues.

The financials provide a comprehensive view of the new ’One Lonza’ structure and its financial performance in the fiscal year 2024 and the first half of 2024. This information comes ahead of the company’s first-half results for 2025, which will be released on July 23.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.